Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Luckily for you, we built StockStory to help you separate the good from the bad. That said, here is one cash-producing company that leverages its financial strength to beat its competitors and two that may struggle to keep up.
Two Stocks to Sell:
Himax (HIMX)
Trailing 12-Month Free Cash Flow Margin: 3.3%
Taiwan-based Himax Technologies (NASDAQ: HIMX) is a leading manufacturer of display driver chips and timing controllers used in TVs, laptops, and mobile phones.
Why Do We Steer Clear of HIMX?
- Annual sales declines of 7% for the past five years show its products and services struggled to connect with the market during this cycle
- Free cash flow margin shrank by 16.3 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- High net-debt-to-EBITDA ratio of 6× could force the company to raise capital on unfavorable terms if market conditions deteriorate
At $14.10 per share, Himax trades at 17.3x forward P/E. Read our free research report to see why you should think twice about including HIMX in your portfolio.
Visteon (VC)
Trailing 12-Month Free Cash Flow Margin: 4.9%
Originally spun off from Ford Motor Company in 2000, Visteon (NYSE: VC) designs and manufactures cockpit electronics for vehicles, including digital instrument clusters, displays, infotainment systems, and battery management systems.
Why Is VC Not Exciting?
- Annual sales declines of 2.2% for the past two years show its products and services struggled to connect with the market during this cycle
- Gross margin of 12.3% is below its competitors, leaving less money to invest in areas like marketing and R&D
- Earnings per share have dipped by 33.3% annually over the past two years, which is concerning because stock prices follow EPS over the long term
Visteon is trading at $87.10 per share, or 9.5x forward P/E. To fully understand why you should be careful with VC, check out our full research report (it’s free).
One Stock to Buy:
Humana (HUM)
Trailing 12-Month Free Cash Flow Margin: 1.4%
With over 80% of its revenue derived from federal government contracts, Humana (NYSE: HUM) provides health insurance plans and healthcare services to approximately 17 million members, with a strong focus on Medicare Advantage plans for seniors.
Why Is HUM a Good Business?
- Offerings and unique value proposition resonate with customers, as seen in its above-market 15.1% annual sales growth over the last two years
- Enormous revenue base of $145.8 billion gives it leverage over plan holders and advantageous reimbursement terms with healthcare providers
- ROIC punches in at 32.9%, illustrating management’s expertise in identifying profitable investments
Humana’s stock price of $403.26 implies a valuation ratio of 32.8x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
